A bivalent cyclic RGD–siRNA conjugate enhances the antitumor effect of apatinib via co-inhibiting VEGFR2 in non-small cell lung cancer xenografts

References

• Alday-Parejo B, Stupp R, Ruegg C. (2019). Are integrins still practicable targets for anti-cancer therapy? Cancers (Basel) 11:978.
   PubMed Web of Science ®Google Scholar
• Arosio D, Casagrande C. (2016). Advancement in integrin facilitated drug delivery. Adv Drug Deliv Rev 97:111–43.
   PubMed Web of Science ®Google Scholar
• Barata P, Sood AK, Hong DS. (2016). RNA-targeted therapeutics in cancer clinical trials: current status and future directions. Cancer Treat Rev 50:35–47.
   PubMed Web of Science ®Google Scholar
• Beer AJ, Schwaiger M. (2008). Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev 27:631–44.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424.
   PubMed Web of Science ®Google Scholar
• Caillaud M, El Madani M, Massaad-Massade L. (2020). Small interfering RNA from the lab discovery to patients' recovery. J Control Release 321:616–28.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307.
   PubMed Web of Science ®Google Scholar
• Cen B, Liao W, Wang Z, et al. (2018). Gelofusine attenuates tubulointerstitial injury induced by cRGD-conjugated siRNA by regulating the TLR3 signaling pathway. Mol Ther Nucleic Acids 11:300–11.
   PubMedGoogle Scholar
• Cen B, Wei Y, Huang W, et al. (2018). An efficient bivalent cyclic RGD-PIK3CB siRNA conjugate for specific targeted therapy against glioblastoma in vitro and in vivo. Mol Ther Nucleic Acids 13:220–32.
   PubMedGoogle Scholar
• Chen S, Liu X, Gong W, et al. (2013). Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer lung cancer xenografts. Oncol Rep 29:260–8.
   PubMed Web of Science ®Google Scholar
• Debacker AJ, Voutila J, Catley M, et al. (2020). Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol Ther 28:1759–71.
   PubMed Web of Science ®Google Scholar
• Fan Y, Zhao J, Wang Q, et al. (2020). Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): a multicenter, two-stage, phase 2 trial. J Thorac Oncol 16:299–309.
   PubMed Web of Science ®Google Scholar
• Hall RD, Le TM, Haggstrom DE, et al. (2015). Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 4:515–23.
   PubMed Web of Science ®Google Scholar
• He S, Cen B, Liao L, et al. (2017). A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo. Drug Deliv 24:471–81.
   PubMed Web of Science ®Google Scholar
• Hu B, Zhong L, Weng Y, et al. (2020). Therapeutic siRNA: state of the art. Sig Transduct Target Ther 5:1–25.
   PubMed Web of Science ®Google Scholar
• Lee SH, Kang YY, Jang HE, et al. (2016). Current preclinical small interfering RNA (siRNA)-based conjugate systems for RNA therapeutics. Adv Drug Deliv Rev 104:78–92.
   PubMed Web of Science ®Google Scholar
• Liao W, Qin Y, Liao L, et al. (2018). Protective effect of gelofusine against cRGD–siRNA-induced nephrotoxicity in mice. Ren Fail 40:187–95.
   PubMed Web of Science ®Google Scholar
• Liu L, Liu X, Xu Q, et al. (2014a). Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy. Int J Nanomedicine 9:3509–26.
   PubMed Web of Science ®Google Scholar
• Liu X, Wang W, Samarsky D, et al. (2014b). Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA. Nucleic Acids Res 42:11805–17.
   PubMed Web of Science ®Google Scholar
• Manzo A, Montanino A, Carillio G, et al. (2017). Angiogenesis inhibitors in NSCLC. Int J Mol Sci 18:2021.
   PubMed Web of Science ®Google Scholar
• Mok T, Gorbunova V, Juhasz E, et al. (2014). A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015). J Thorac Oncol 9:848–55.
   PubMed Web of Science ®Google Scholar
• Ozcan G, Ozpolat B, Coleman RL, et al. (2015). Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 87:108–19.
   PubMed Web of Science ®Google Scholar
• Pajares MJ, Agorreta J, Larrayoz M, et al. (2012). Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol 30:1129–36.
   PubMed Web of Science ®Google Scholar
• Piperdi B, Merla A, Perez-Soler R. (2014). Targeting angiogenesis in squamous non-small cell lung cancer. Drugs 74:403–13.
   PubMed Web of Science ®Google Scholar
• Ruger J, Ioannou S, Castanotto D, et al. (2020). Oligonucleotides to the (gene) rescue: FDA approvals 2017–2019. Trends Pharmacol Sci 41:27–41.
   PubMed Web of Science ®Google Scholar
• Setten RL, Rossi JJ, Han SP. (2019). The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov 18:421–46.
   PubMed Web of Science ®Google Scholar
• Shen J, Liu H, Mu C, et al. (2017). Multi-step encapsulation of chemotherapy and gene silencing agents in functionalized mesoporous silica nanoparticles. Nanoscale 9:5329–41.
   PubMed Web of Science ®Google Scholar
• Shen J, Zhang W, Qi R, et al. (2018). Engineering functional inorganic–organic hybrid systems: advances in siRNA therapeutics. Chem Soc Rev 47:1969–95.
   PubMed Web of Science ®Google Scholar
• Tian S, Quan H, Xie C, et al. (2011). YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 102:1374–80.
   PubMed Web of Science ®Google Scholar
• Weng Y, Xiao H, Zhang J, et al. (2019). RNAi therapeutic and its innovative biotechnological evolution. Biotechnol Adv 37:801–25.
   PubMed Web of Science ®Google Scholar
• Wittrup A, Lieberman J. (2015). Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet 16:543–52.
   PubMed Web of Science ®Google Scholar
• Xue JM, Astere M, Zhong MX, et al. (2018). Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis. Onco Targets Ther 11:6119–28.
   PubMed Web of Science ®Google Scholar
• Yang Q, Chen T, Wang S, et al. (2020). Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself. Angiogenesis 23:279–98.
   PubMed Web of Science ®Google Scholar
• Zhang H. (2015). Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther 9:6075–81.
   PubMed Web of Science ®Google Scholar